Food, Drugs, Healthcare, Life Sciences

On June 12, the U.S. Court of Appeals for the Eighth Circuit upheld a federal district court's order that preliminarily enjoined enforcement of Minnesota's law controlling price increases...

This week, the Board of New York's Metropolitan Transportation Authority voted to allow alcohol advertising on New York City buses, subways, and elsewhere in the City's transit system.

With a focus on increasing business investment and growing industries of the future, the UK's Industrial Strategy released this week sets out its approach to driving long-term growth. Life sciences is identified...

With a focus on increasing business investment and growing industries of the future, the UK's Industrial Strategy released this week sets out its approach to driving long-term growth. Life sciences is identified...

The new Product Liability Directive marks the most significant overhaul of product liability law in nearly four decades.

The most recent and stringent legislative effort to restrict private equity investment in medical practices became law on June 9, 2025, when Oregon Gov. Tina Kotek signed Senate Bill 951 (SB 951).

On June 24, HRSA announced that it had issued new grant award terms to its HRSA-funded health centers to provide insulin and injectable epinephrine at or below the 340B price paid by the health center for the drugs.

On June 18, the Supreme Court issued an opinion in United States v. Skrmetti upholding a Tennessee law banning the provision of gender-affirming care for youth under 18...

With a focus on increasing business investment and growing industries of the future, the UK's Industrial Strategy released this week sets out its approach to driving long-term growth. Life sciences is identified...

On June 8, 2012, Genentech’s lawsuit seeking a declaration that US Patent No. 6,733,752 was invalid and not-infringed by Genentech’s trastuzumab product (HERCEPTIN).

Health Canada specifically contemplates certain proteins as SEBs in its Guidance, although Health Canada has not limited SEBs to only particular classes of drugs.

On May 23, 2012, the Federal Court held that Merck Frosst Canada Ltd. ("Merck") is liable to Apotex Inc. ("Apotex") for damages under section 8 of the Patented Medicines (Notice of Compliance) Regulations (the "Regulations"), but exercised its discretion to reduce the amount of compensation payable based on a defence of ex turpi causa.